364 results on '"Wagner, Anita K."'
Search Results
2. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020
3. Effect of a national antibiotic stewardship intervention in China targeting carbapenem overuse: An interrupted time-series analysis
4. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway
5. Financial toxicity of withdrawn poly (ADP-ribose) polymerase inhibitor indications for ovarian cancer
6. Newly approved cancer drugs in China — innovation and clinical benefit
7. Essential medicines for universal health coverage
8. Use of Palliative Care Among Commercially Insured Patients With Metastatic Cancer Between 2001 and 2016
9. Changing Tides? Anticancer Biologic and Biosimilar Use in Medicare Part B, 2019-2021
10. Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program
11. Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer
12. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data
13. Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis
14. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015
15. Evaluation of Switching Patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs
16. 1-year impact of supervision, performance assessment, and recognition strategy (SPARS) on prescribing and dispensing quality in Ugandan health facilities
17. Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe
18. A rapidly changing global medicines environment: How adaptable are funding decision-making systems?
19. Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia
20. Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand
21. Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway
22. Thirty Years of Media Coverage on High Drug Prices in the United States—A Never-Ending Story or a Time for Change?
23. Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries
24. The Brazilian private pharmaceutical market after the first ten years of the generics law
25. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
26. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
27. New-Onset Cancer Cases in FDA's Sentinel System: A Large Distributed System of US Electronic Healthcare Data
28. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: An interrupted time series study
29. Quality Reporting by Payers: A Mixed-Methods Study of Provider Perspectives and Practices
30. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China
31. Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer
32. Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage
33. Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil
34. Does access to medicines differ by gender? Evidence from 15 low and middle income countries
35. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data.
36. Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries/Effet de la recession economique sur la politique pharmaceutique et les ventes de medicaments dans huit pays europeens/El efecto de la recesion economica sobre la politica farmaceutica y la venta de medicinas en ocho paises europeos
37. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018
38. Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval
39. Out-of-Pocket Burden of Health Care Spending and the Adequacy of the Medicare Part D Low-Income Subsidy
40. Simulation-based power calculation for designing interrupted time series analyses of health policy interventions
41. Communication of Survival Data in US Food and Drug Administration–Approved Labeling of Cancer Drugs
42. Childhood Cancer Drugs in China: An Overview and Comparison of Regulatory Approvals in China and the United States
43. Impacts of a new insurance benefit with capitated provider payment on healthcare utilization, expenditure and quality of medication prescribing in China
44. Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan†
45. Effects of state surveillance on new post-hospitalization benzodiazepine use
46. Methods for estimating confidence intervals in interrupted time series analyses of health interventions
47. 30 years of media coverage on high drug prices in the US – a never-ending story or a time for change?
48. Forecasting asparaginase quantity required to treat pediatric ALL in LMICs using ACCESS FORxECAST.
49. Forecasting essential childhood cancer drug need: An innovative model‐based approach
50. Article 3: 1-year impact of supervision, performance assessment, and recognition strategy (SPARS) on prescribing and dispensing quality in Ugandan health facilities
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.